Rappta Therapeutics and SpringWorks Partner on Molecular Glue Targeting PP2A

Rappta Therapeutics (Rappta), focused to creating first-in-class anti-cancer therapies that activate protein phosphatase 2A (PP2A), has announced a global exclusive licensing agreement with SpringWorks Therapeutics (SpringWorks) for RPT04402, a novel molecular glue targeting specific Protein Phosphatase 2A (PP2A) complexes.

Rappta’s technologies that reactivate PP2A, created from its unique high-resolution structural information, have the potential to develop a new category of anti-cancer medications for addressing a wide array of human cancers. PP2A is an essential enzyme involved in the regulation of protein de-phosphorylation, and its reactivation is vital for tumour suppression; however, it has traditionally been challenging to target.

PP2A mutations act as oncogenic drivers in specific molecular subsets of uterine cancer and signify a targetable group of patients with significant clinical needs. In pre-clinical models of uterine cancer with PP2A mutations, RPT0402 resulted in quick, significant, and long-lasting tumor reductions as a standalone treatment.

Sunjeet Sawhney, chief executive officer of Rappta Therapeutics, commented: “Rappta is the only company to have successfully targeted PP2A, a notoriously difficult and undruggable target. Data we generated demonstrated the potential of RPT04402 for treating large, underserved patient populations. SpringWorks, a leader in the targeted oncology space, has the expertise and knowledge to accelerate the further development of our first in class asset. I would like to thank our team and investors who have supported our journey and we look forward to following the progress made in this area”